lonidamine

03/01/1997 - "Lonidamine (LND) is a relatively new anti-cancer drug, and several clinical trials have indicated that it may be effective in combinations with other therapeutic modalities. "
03/01/2003 - "Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors."
01/01/1996 - "In addition, the study indicated that the duration of lonidamine administration after injection of the cytotoxic drug influenced the tumor response and that prolonged treatment resulted in greater efficacy. "
05/01/1989 - "In an effort to determine the radiobiologic factors involved with the potentiating effect of radiation by lonidamine, a series of cell culture studies were carried out using multicellular tumor spheroids (MTS) of HeLa Cells. "
05/01/1989 - "The previous study of lonidamine and radiation using two murine tumors demonstrated that tumor cure rates were significantly increased by radiation and concomitant lonidamine. "

03/01/1997 - "Comparison of action of the anti-neoplastic drug lonidamine on drug-sensitive and drug-resistant human breast cancer cells: 31P and 13C nuclear magnetic resonance studies."
09/01/1991 - "In a phase II study 32 patients with previously treated advanced breast cancer were given Lonidamine in a daily divided oral dose of 600 mg. Of 28 patients evaluable for response, three (11%) achieved a partial response (4-24+ months) and three (11%) a minor response. "
09/01/1991 - "A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer."
11/01/1990 - "The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. "
11/01/1990 - "Phase II study of lonidamine in patients with metastatic breast cancer. "

05/01/1998 - "These observations confirm the results of in vitro studies which suggest that the combined effect of lonidamine and hyperthermia is enhanced under acidic conditions. "
04/01/1991 - "The clinical trials summarized include: A) the combination of 41.8 degrees C whole body hyperthermia (WBH) and the chemotherapeutic drug lonidamine; B) the use of total body irradiation (TBI) (12.5 cGy twice a week, every other week--total planned dose 150 cGy) and daily oral lonidamine; C) the juxtapositioning of TBI (with the same fraction schema) and 41.8 degrees C WBH x 75 min--initiated 10 min after TBI. "
04/01/1990 - "These studies evaluated the use of either 41.8 degrees C whole body hyperthermia (WBH), or the nonmyelosuppressive chemotherapeutic drug, lonidamine (LON), as an adjunct to total body irradiation (TBI) (12.5 cGy twice a week, every other week for a planned total dose of 150 cGy). "
09/01/1995 - "Lonidamine (50 mg/kg) administered once or twice daily produced approximately additive tumour growth delay with whole-body hyperthermia (60 min to 42 degrees C and 60 min at 42 degrees C). "
07/01/1995 - "The pharmacokinetics and toxicity of intravenous lonidamine were investigated in dogs receiving four cycles of lonidamine (400 or 800 mg/m2) +/- whole-body hyperthermia (WBH). "

11/01/1988 - "Effect of lonidamine on human malignant gliomas: biochemical studies."
07/01/1998 - "Disturbance of HK binding to mitochondria by lonidamine led to inhibition of cells and xenografted-glioma growth. "
07/01/1990 - "Lonidamine in the combined treatment of malignant gliomas. "
06/01/1989 - "Survival of U-87 MG glioma cells was also strongly pH dependent, a 2-h exposure to 50 micrograms/mL lonidamine at pH 7.4 did not cause cell death; however, survival dropped to 84% of the control at pH 6.65."
06/01/1989 - "The U-87 MG glioma cells did not show ultrastructural disruption after 1-h treatment with lonidamine at concentrations up to 200 micrograms/mL at pH 6.7. "

06/01/1986 - "The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of lonidamine, given in an escalating oral daily schedule in patients with measurable advanced renal cell carcinoma. "
06/01/1986 - "Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study."
04/01/1991 - "These data suggest that lonidamine and high-dose tamoxifen are moderately effective in widespread renal cell carcinoma where treatment intention is palliative."
04/01/1991 - "Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study."
04/01/1991 - "Sixty patients with metastatic renal cell carcinoma were entered into an ongoing randomized phase II study with lonidamine, 350 mg/m2 orally daily (arm A) and high dose tamoxifen, 150 mg/m2 orally daily for 6 months, afterwards 50 mg/m2 (arm B), until tumor progression. "